Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global Cancer Biomarkers Market by Cancer Type (Prostate, Breast, Lung, Colorectal, Cervical) by Profiling Technology (OMICS, Imaging, Immunoassays, Cytogenetics, Bioinformatics)– Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

GLOBAL CANCER BIOMARKERS MARKET was valued at USD 13.49 Billion in the year 2017. Global Cancer Biomarkers market is further estimated to grow at a CAGR of 13.8% from 2018 to reach USD 29.3 Billion by the year 2023.

The Global Cancer Biomarkers is segmented as by cancer type, by profiling technology, by biomarkers, and by region. On the basis of the type of cancer the market is segmented as Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer and Others of which breast cancer holds the highest market share.

On the basis of Profiling Technology, the Global Cancer Biomarkers market is segmented as OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, and Bioinformatics of which OMICS Technology is expected to hold the highest market share in the forecasted period.

On the other hand, by a Biomarkers Type, the market is segmented as Protein Biomarkers, Genetic Biomarkers and Others for this protein biomarker segment are expected to grow at highest CAGR during the year 2018-2023. The large share of this segment is mainly attributed to the tremendous potential of protein biomarkers in cancer detection.

Asia Pacific region holds the highest market share in 2017 and North America is considered as the fastest growing market in the forecasted period. At a country level, Japan, China, and South Korea are projected to grow strongly in the coming years. Factors such as rising incidence of cancer, increasing use of biomarker tests for diagnostic purposes and government support to research institutes and universities are further driving the growth of this market in the APAC region.

Drivers:

            Increased Incidences of Cancer Globally

            Higher Acceptance for Treatment in Developing Regions

Restraints:

            High Cost of Diagnosis and Reimbursement Issues

Opportunities:

            Technological and Scientific advancements   

            Emerging Economies

Challenges:

            Unfavorable Regulatory framework and policies

23andMe (U.S), Agilent Technologies (U.S), Abbott Laboratories, Inc. (U.S), Biomerieux (France), Hologic, Inc. (U.S),Roche Holding AG (Switzerland), Illumina, Inc. (U.S), Roche Diagnostics (Switzerland), GE Healthcare (U.S) and Bio-Rad Laboratories (U.S)are some of the key players in the Cancer Biomarkers Market. Rising research and development expenses to address the changing demand of end users. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of the top players in the last 5 years.

Key Benefits for Stakeholders

Manufacturing companies of diagnostics kits and imaging instrument providers

Contract research organizations (CROs)

Healthcare organizations and R&D Institutes

Various Research organizations and consulting firms

The government, Regulatory bodies, and consumers

By Cancer Type

Prostate Cancer

Breast Cancer

Lung Cancer

Colorectal Cancer

Cervical Cancer

Others

By Profiling Technology

OMICS Technology

Imaging Technology

Immunoassays

Cytogenetics

Bioinformatics

By Biomarkers Type

Protein Biomarkers

Genetic Biomarkers 

Others

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

23andMe

Agilent Technologies

Abbott Laboratories, Inc.

Biomerieux

Hologic, Inc.

Roche Holding AG

Illumina, Inc.

Roche Diagnostics

GE Healthcare

Bio-Rad Laboratories

(Another brief information of 10 companies will be provided in the report)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6.      Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottoms-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Cancer Biomarkers Market, By Cancer Type

6.1 Prostate Cancer

6.2 Breast Cancer

6.3 Lung Cancer

6.4 Colorectal Cancer

6.5 Cervical Cancer

6.6 Others

7. Cancer Biomarkers Market, By Profiling Technology

7.1 OMICS Technology

7.2 Imaging Technology

7.3 Immunoassays

7.4 Cytogenetics

7.5 Bioinformatics

8. Cancer Biomarkers Market, By Biomarkers Type

8.1 Protein Biomarkers

8.2 Genetic Biomarkers 

8.3 Others

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. U.K.

       9.3.2. Germany

       9.3.3. France

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. China

       9.4.2. Malaysia

       9.4.3. South Korea

       9.4.4. India

            9.4.5 Ro APAC

9.5. RoW

       9.5.1. Latin America

       9.5.2. Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 23andMe

10.2 Agilent Technologies

10.3 Abbott Laboratories, Inc.

10.4 Biomerieux

10.5 Hologic, Inc.

10.6 Roche Holding AG

10.7 Illumina, Inc.

10.8 Roche Diagnostics

10.9 GE Healthcare

10.10 Bio-Rad Laboratories

(A brief overview of 10 companies is also provided.)

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        11.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

 

List of Tables (46 Tables)

Table 1 Conventional Diagnostics Vs. Diagnostic Biomarker Techniques
Table 2 Worldwide Estimated Incidence And Prevalence Of All Cancer Types (2012)
Table 3 Revenue Generation Of Biological And Targeted Drugs In 2013 ($Million)
Table 4 Key Products With Their Patent Expiry Dates
Table 5 Collaborations And Acquisitions For Development Of Cancer Drugs
Table 6 Patents Registered/Approved In The U.S., Europe, Canada, China, Japan, And Others, 2013 Through 2016
Table 7 U.S.: Patent Analysis By Market Participant, 2017-2018
Table 8 Europe: Patent Analysis By Market Participant, 2017-2018
Table 9 China: Patent Analysis By Market Participant, 2010-2016
Table 10 Canada: Patent Analysis By Market Participant, 2010-2016
Table 11 Japan: Patent Analysis By Market Participant, 2017-2018
Table 12 Others: Patent Analysis By Market Participant, 2017-2018
Table 13 Clinical Trials: Cancer Biomarkers
Table 14 Cancer Biomarkers Market, By Profiling Technology, 2018-2023 ($Million)
Table 15 World Omics Technology Market, By Type, 2018-2023 ($Million)
Table 16 World Omics Technology Market, By Geography, 2018-2023 ($Million)
Table 17 Global Genomics Technology Market, By Type, 2018-2023 ($Million)
Table 1 Global Proteomics Technology Market, By Type, 2018-2023 ($Million)
Table 2 Global Other Omics Technology Market, By Type, 2018-2023 ($Million)
Table 3 Global Imaging Technology Market, By Type, 2018-2023 ($Million)
Table 4 Global Imaging Technology Market, By Geography, 2018-2023 ($Million)
Table 5 Global Immunoassays Market, By Type, 2018-2023 ($Million)
Table 6 Global Immunoassays Market, By Geography, 2018-2023 ($Million)
Table 7 Global Cytogenetics-Based Tests Market, By Type, 2018-2023 ($Million)
Table 8 Global Cytogenetics-Based Tests Market, By Geography, 2018-2023 ($Million)
Table 9 Global Cancer Biomarkers Market, By Type, 2018-2023 ($Million)
Table 10 Global Genetic Biomarkers Market, By Geography, 2018-2023 ($Million)
Table 11 Global Protein Biomarkers Market, By Geography, 2018-2023 ($Million)
Table 12 Global Glyco-Biomarkers Market, By Geography, 2018-2023 ($Million)
Table 13 Cancer Biomarkers Market, By Cancer Type, 2018-2023 ($Million)
Table 14 Global Cancer Biomarkers For Lung Cancer, By Geography, 2018-2023 ($Million)
Table 15 Global Cancer Biomarkers For Breast Cancer, By Geography, 2018-2023 ($Million)
Table 16 Global Cancer Biomarkers For Colorectal Cancer Market, By Geography, 2018-2023 ($Million)
Table 17 Global Cancer Biomarkers For Prostate Cancer Market, By Geography, 2018-2023 ($Million)
Table 18 Global Cancer Biomarkers For Stomach Cancer Market, By Geography, 2018-2023 ($Million)
Table 19 Global Cancer Biomarkers For Other Cancers, By Geography, 2018-2023 ($Million)
Table 20 Cancer Biomarkers Market, By Type, 2018-2023 ($Million)
Table 21 Diagnostics Market, By Geography, 2018-2023 ($Million)
Table 22 Drug Discovery And Development Market, By Geography, 2018-2023 ($Million)
Table 23 Prognostics Market, By Geography, 2018-2023 ($Million)
Table 24 Risk Assessment Market, By Geography, 2018-2023 ($Million)
Table 25 Others Market, By Geography, 2018-2023 ($Million)
Table 26 Cancer Biomarkers Market, By Geography, 2014-2020 ($Million)
Table 27 North America Cancer Biomarkers Market, By Profiling Technology, 2018-2023 ($Million)
Table 28 North America Cancer Biomarkers Market, By Type, 2018-2023 ($Million)
Table 29 North America Cancer Biomarkers Market, By Cancer Type, 2018-2023 ($Million)
Table 30 North America Cancer Biomarkers Market, By Application, 2018-2023 ($Million)
Table 31 North American Cancer Biomarkers Market, By Country, 2018-2023 ($Million)
Table 32 European Cancer Biomarkers Market, By Profiling Technology, 2018-2023 ($Million)
Table 33 European Cancer Biomarkers Market, By Type, 2018-2023 ($Million)
Table 34 European Cancer Biomarkers Market, By Cancer Type, 2018-2023 ($Million)
Table 35 European Cancer Biomarkers Market, By Application, 2018-2023 ($Million)
Table 36 European Cancer Biomarkers Market, By Country, 2018-2023 ($Million)
Table 37 Asia-Pacific Cancer Biomarkers Market, By Profiling Technology, 2018-2023 ($Million)
Table 38 Asia-Pacific Cancer Biomarkers Market, By Type, 2018-2023 ($Million)
Table 39 Asia-Pacific Cancer Biomarkers Market, By Cancer Type, 2018-2023 ($Million)
Table 40 Asia-Pacific Cancer Biomarkers Market, By Application, 2018-2023 ($Million)
Table 41 Asia-Pacific Cancer Biomarkers Market, By Country, 2018-2023 ($Million)
Table 42 Lamea Cancer Biomarkers Market, By Profiling Technology, 2018-2023 ($Million)
Table 43 Lamea Cancer Biomarkers Market, By Type, 2018-2023 ($Million)
Table 44 Lamea Cancer Biomarkers Market, By Cancer Type, 2018-2023 ($Million)
Table 45 Lamea Cancer Biomarkers Market, By Application, 2018-2023 ($Million)
Table 46 Lamea Cancer Biomarkers Market, By Country, 2018-2023 ($Million)

 

List of Figures (36 Figures)

Fig. 1 Cancer Biomarkers Market: Segmentation
Fig. 2 Top Impacting Factors: Cancer Biomarkers Market, 2018-2023
Fig. 3 Percentage (%) Of New Cancers Cases Diagnosed In 2012
Fig. 4 Top Investment Pockets: Cancer Biomarkers, 2018-2023
Fig. 5 Top Winning Strategies: Percentage Distribution
Fig. 6 Top Winning Strategies: Nature & Type
Fig. 7 Types Of Strategies Distribution
Fig. 8 Detailed Structure Of Companies And Nature Of Strategies
Fig. 9 Detailed Structure Of Companies And Type Of Strategies
Fig. 10 Porters Five Forces Analysis
Fig. 11 Top Player Positioning, 2017
Fig. 12 Patents Registered/Approved In The World, 2017-2018
Fig. 13 U.S.: Patent Analysis By Market Participant, 2017-2018
Fig. 14 Europe: Patent Analysis By Market Participant, 2017-2018
Fig. 15 China: Patent Analysis By Market Participant, 2017-2018
Fig. 16 Canada: Patent Analysis By Market Participant, 2017-2018
Fig. 17 Japan: Patent Analysis By Market Participant, 2017-2018
Fig. 18 Others: Patent Analysis By Market Participant, 2017-2018
Fig. 19 U.S.: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 20 Canada: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 21 Mexico: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 22 Germany: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 23 U.K.: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 24 France: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 25 Italy: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 26 Russia: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 27 Rest Of Europe: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 28 Japan: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 29 China: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 30 India: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 31 Australia: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 32 Rest Of Asia-Pacific: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 33 Brazil: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 34 Saudi Arabia: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 35 UAE: Cancer Biomarkers Market Size, 2018-2023 ($Million)
Fig. 36 Rest Of Lamea: Cancer Biomarkers Market Size, 2018-2023 ($Million)

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports